These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 35807171)
41. PCSK9 targets important for lipid metabolism. Schulz R; Schlüter KD Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216 [TBL] [Abstract][Full Text] [Related]
42. Recent patents on PCSK9: a new target for treating hypercholesterolemia. Li H; Li H; Ziegler N; Cui R; Liu J Recent Pat DNA Gene Seq; 2009; 3(3):201-12. PubMed ID: 19601924 [TBL] [Abstract][Full Text] [Related]
43. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
44. Nucleic Acid-Based Therapies for Atherosclerosis. Mäkinen P; Ruotsalainen AK; Ylä-Herttuala S Curr Atheroscler Rep; 2020 Feb; 22(2):10. PubMed ID: 32034521 [TBL] [Abstract][Full Text] [Related]
45. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside. Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441 [TBL] [Abstract][Full Text] [Related]
46. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799 [TBL] [Abstract][Full Text] [Related]
47. The Future of Lipid-lowering Therapy. Zwol WV; Rimbert A; Kuivenhoven JA J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31340607 [TBL] [Abstract][Full Text] [Related]
48. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Shimada YJ; Cannon CP Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287 [TBL] [Abstract][Full Text] [Related]
49. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
50. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]